Literature DB >> 7373531

Effect of particle size on ophthalmic bioavailability of dexamethasone suspensions in rabbits.

R D Schoenwald, P Stewart.   

Abstract

Three suspensions of 0.1% [3H]dexamethasone were prepared with mean particle sizes of 5.75, 11.5, and 22.0 micron. The suspensions were dosed topically to the right eyes of rabbits. Their bioavailability was compared by measuring aqueous humor and corneal levels over 5 hr. A statistically significant rank-order correlation was observed between increasing drug levels and decreasing particle size.

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 7373531     DOI： 10.1002/jps.2600690407

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN： 0022-3549            Impact factor:   3.534


  12 in total

Review 1.  Locally administered ocular corticosteroids: benefits and risks.

Authors:  Charles N J McGhee; Simon Dean; Helen Danesh-Meyer
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 2.  Pharmacokinetics of ophthalmic corticosteroids.

Authors:  C N McGhee
Journal:  Br J Ophthalmol       Date:  1992-11       Impact factor: 4.638

3.  General Pharmacokinetic Model for Topically Administered Ocular Drug Dosage Forms.

Authors:  Feng Deng; Veli-Pekka Ranta; Heidi Kidron; Arto Urtti
Journal:  Pharm Res       Date:  2016-07-18       Impact factor: 4.200

4.  Application of Mechanistic Ocular Absorption Modeling and Simulation to Understand the Impact of Formulation Properties on Ophthalmic Bioavailability in Rabbits: a Case Study Using Dexamethasone Suspension.

Authors:  Maxime Le Merdy; Jianghong Fan; Michael B Bolger; Viera Lukacova; Jessica Spires; Eleftheria Tsakalozou; Vikram Patel; Lin Xu; Sharron Stewart; Ashok Chockalingam; Suresh Narayanasamy; Rodney Rouse; Murali Matta; Andrew Babiskin; Darby Kozak; Stephanie Choi; Lei Zhang; Robert Lionberger; Liang Zhao
Journal:  AAPS J       Date:  2019-05-20       Impact factor: 4.009

Review 5.  Clinical pharmacokinetics of various topical ophthalmic delivery systems.

Authors:  J P Frangie
Journal:  Clin Pharmacokinet       Date:  1995-08       Impact factor: 6.447

6.  In Vitro Modeling of Skin Barrier Disruption and its Recovery by Ceramide-Based Formulations.

Authors:  Barbora Amélie Čuříková-Kindlová; Aneta Vovesná; Anna Nováčková; Jarmila Zbytovská
Journal:  AAPS PharmSciTech       Date:  2021-12-14       Impact factor: 3.246

7.  Effect of 2-hydroxypropyl-beta-cyclodextrin on the ocular absorption of dexamethasone and dexamethasone acetate.

Authors:  A Usayapant; A H Karara; M M Narurkar
Journal:  Pharm Res       Date:  1991-12       Impact factor: 4.200

8.  Physiologically Based Pharmacokinetic Model to Support Ophthalmic Suspension Product Development.

Authors:  Maxime Le Merdy; Ming-Liang Tan; Andrew Babiskin; Liang Zhao
Journal:  AAPS J       Date:  2020-01-06       Impact factor: 4.009

9.  Role of hydroxypropyl-β-cyclodextrin on freeze-dried and gamma-irradiated PLGA and PLGA-PEG diblock copolymer nanospheres for ophthalmic flurbiprofen delivery.

Authors:  Estefanía Vega; M Antònia Egea; Ana Cristina Calpena; Marta Espina; M Luisa García
Journal:  Int J Nanomedicine       Date:  2012-03-09

10.  Preparation and In Vitro/Ex Vivo Evaluation of Moxifloxacin-Loaded PLGA Nanosuspensions for Ophthalmic Application.

Authors:  Meetali Mudgil; Pravin K Pawar
Journal:  Sci Pharm       Date:  2013-02-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.